Status:
UNKNOWN
Safety and Immunogenicity of COVID-19 Vaccine Booster in Patients With Liver Diseases
Lead Sponsor:
Huashan Hospital
Collaborating Sponsors:
LanZhou University
Xingtai People's Hospital
Conditions:
COVID-19
Vaccine Reaction
Eligibility:
All Genders
18+ years
Brief Summary
Previous studies should that patients with chronic liver diseases, cirrhosis, hepatocellular carcinoma and post-liver-trasplant status had lower immunological response to SARS-CoV-2 vaccines than heal...
Eligibility Criteria
Inclusion
- Previously vaccinated with two doses of SARS-CoV-2 vaccines and planning to get booster vaccination.
- Clinically or pathologically diagnosed with pre-existing liver disease, including: chronic liver diseases, cirrhosis, liver cancer, liver transplant subjects, etc.
- Understanding and willing to comply with the study procedures and provides written informed consent.
Exclusion
- Pregnancy or lactation.
- Active or known history of SARS-CoV-2 infection.
- Diseases causing immunosuppressive or immunodeficient status or autoimmune diseases.
- A history of discontinuing anti-HBV agents in recent three months.
Key Trial Info
Start Date :
February 10 2022
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
December 20 2022
Estimated Enrollment :
1000 Patients enrolled
Trial Details
Trial ID
NCT05204602
Start Date
February 10 2022
End Date
December 20 2022
Last Update
February 14 2022
Active Locations (19)
Enter a location and click search to find clinical trials sorted by distance.
1
The Second Affiliated Hospital of Chongqing Medical University
Chongqing, Chongqing Municipality, China
2
The First Hospital of Lanzhou University
Lanzhou, Gansu, China, 730000
3
Baoding people's Hospital
Baoding, Hebei, China
4
Xingtai People's Hospital
Xingtai, Heibei, China